Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 36

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 36
---
 affirmative vote of holders representing a simple majority of the total voting rights of shareholders present in person or by proxy who (being entitled to vote) vote on the matter will be required to pass this resolution. THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE AUTHORIZATION OF ALLOTMENT OF SHARES. 26 TABLE OF CONTENTS RESOLUTION 13 DISAPPLICATION OF STATUTORY PRE-EMPTION RIGHTS When the directors of an English public company allot equity securities (being ordinary shares or rights to subscribe for or convert any security into shares (“Share Rights”)) for cash, the company must first offer those equity securities on the same or more favorable terms to existing shareholders of the company on a pro rata basis (commonly referred to as the “statutory pre-emption right”) unless this statutory pre-emption right is disapplied, or opted-out of, by approval of the shareholders. At the 2021 GM, our shareholders disapplied the statutory pre-emption right in respect of the allotment of equity securities by our directors pursuant to the relevant allotment authority for a period of up to five years until February 3, 2026. Resolution 13 will be proposed as a special resolution to allot equity securities (as defined in section 560 of the Companies Act) for cash in respect of shares with an aggregate nominal value of up to £150,000 (equal to 75 million ordinary shares with a nominal value of £0.002 each), without first offering them to existing shareholders in proportion to their holdings. Resolution 13 is conditional on the approval of resolution 12 because English law requires that a pre-emption disapplication be given in respect of a particular authorization (general or specific) to allot shares. Resolution 13 will therefore not be passed unless resolution 12 is also approved, notwithstanding that the shareholders may have voted to approve resolution 13. Renewal of this authority would not exempt us from applicable Nasdaq requirements to obtain shareholder approval prior to certain share issuances or to comply with applicable SEC disclosure and other regulations, and our board of directors will continue to focus on and satisfy its fiduciary duties to our shareholders with respect to share issuances. If shareholders do not approve resolution 12 or this resolution 13, the remaining unutilized disapplication of pre-emption rights granted at the 2021 GM will continue to apply until the earlier of February 3, 2026 or such time as it has been fully utilized. Shares issued for cash in excess of such number or after such